Group 1 - The company, Paig BioPharma-B (02565.HK), has entered into a placement agreement with joint placement agents, CITIC Securities and ABC International, to issue 5.136 million shares at a price of HKD 58.41 per share, representing a discount of 10% from the closing price of HKD 64.90 on December 12 [1][2] - The total number of shares to be placed represents approximately 1.84% of the company's issued H shares and about 1.33% of the total issued shares as of the announcement date [1] - If all placement shares are fully placed, the estimated gross proceeds will be approximately HKD 300 million, with net proceeds expected to be around HKD 296 million [2] Group 2 - Approximately 40% of the net proceeds is intended for the construction of a next-generation intelligent research and data platform [2] - About 28% of the net proceeds will be used to repay loans and strengthen the company's capital structure [2] - The remaining proceeds will be allocated for ongoing and planned research of PB-2301 and PB-2309 (12%), establishing a subsidiary in Hong Kong and accelerating overseas business expansion (10%), and general corporate purposes and working capital (10%) [2]
派格生物医药-B(02565.HK)拟配售合共513.6万股 总筹约3亿港元